Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias

    Discovery of a NOCIVA in the Westermarck Research Group by Eleonora Mäkelä

    Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias

    A significant fraction of chronic myeloid leukemia (CML) patients relapse from first-generation (1G) tyrosine kinase inhibitor (TKI) therapy, and this could be prevented by the de novo use of 2G TKIs. However, there are no patient stratification markers to guide clinicians in the selection of frontline TKI therapy for optimal outcomes in CML patients. Here, identical results from two independent CML cohorts indicate that the determination of NOCIVA mRNA levels by clinically approved qPCR platforms from de novo chronic phase CML patients could provide significant support for clinicians in recognizing patients in need of first-line 2G TKI therapy. In acute myeloid leukemia (AML), high NOCIVA/CIP2A ratio at diagnosis could indicate a need for first-line therapy intensification.

    Original Article

    Read the press release at UTU´s webpage (in Finnish): Uusi merkkiaine ennustaa verisyöpien lääkehoidon toimivuutta


    Mar 18, 2021 00:00